These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 152910)

  • 1. [Biological changes during the local administration of small doses of urokinase].
    Michaud A; Aiach M; Fiessinger JN; Vayssairat M; Juillet Y
    Nouv Presse Med; 1978 Oct; 7(35):3151. PubMed ID: 152910
    [No Abstract]   [Full Text] [Related]  

  • 2. [Studies on thrombolytic therapy for venous thrombosis in the extremities--dynamics of plasmin inhibitor and FDP following administration of urokinase (author's transl)].
    Takeuchi S; Shiba T
    Nihon Geka Hokan; 1979 May; 48(3):354-61. PubMed ID: 157109
    [No Abstract]   [Full Text] [Related]  

  • 3. [Experience with urokinase in chronic arterial occlusive disease and long-standing phlebothrombosis].
    Trübestein G; Brecht T; Brecht G; Etzel F
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 2():1948-50. PubMed ID: 1030145
    [No Abstract]   [Full Text] [Related]  

  • 4. [Urokinase in acute and chronic arterial diseases].
    Ciammaichella A; Gori M; Bonacci I
    Clin Ter; 1981 Nov; 99(4):377-81. PubMed ID: 7030591
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biological profile of the 1st 4 hours of a thrombolytic treatment combining urokinase with lysyl-plasminogen].
    Roncato M; Vitoux JF; Pernes JM; Aiach M; Fiessinger JN; Gaux JC; Housset E; Leclerc M
    Ann Biol Clin (Paris); 1985; 43(6):851-5. PubMed ID: 3832977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serial changes in hemostatic molecular markers after urokinase therapy of acute myocardial infarction].
    Goto S; Kawai Y; Watanabe K; Hori S; Abe S; Handa S; Ikeda Y
    Kokyu To Junkan; 1992 Jan; 40(1):89-95. PubMed ID: 1532665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obstructive vascular disease treated by urokinase.
    Mazel MS; Riera R
    Med Trial Tech Q; 1979; 25(3):319-31. PubMed ID: 423742
    [No Abstract]   [Full Text] [Related]  

  • 8. Biochemical and clinical aspects of thrombolysis.
    Verstraete M
    Semin Hematol; 1978 Jan; 15(1):35-54. PubMed ID: 341327
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fibrinolytic system in patients with nephrotic syndrome].
    Andreenko GV; Poliantseva LR; Smirnova TA; Podorol'skaia LV
    Ter Arkh; 1976; 40(2):89-99. PubMed ID: 135367
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical changes noted during intermittent administration of streptokinase.
    Verstraete M; Vermylen J; Schetz J
    Thromb Haemost; 1978 Feb; 39(1):61-8. PubMed ID: 148118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modifications in coagulation parameters induced by treatment associating urokinase (2000 u CTA/kg/h) with heparin.
    Juhan I; Calas MF; Buonocore M; Mathieu P; Isnard G; Cazenave B; Serradimigni A
    Thromb Haemost; 1979 Oct; 42(3):945-54. PubMed ID: 315625
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of urokinase during surgery: a new approach to the treatment of vascular obliterative disease (author's transl)].
    Fiessinger JN; Vayssairat M; Juillet Y; Janneau D; Aiach M; Cormier JM; Housset E
    Ann Med Interne (Paris); 1979; 130(4):215-8. PubMed ID: 475207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment with the urokinase-lysyl plasminogen combination of developmental outbreaks of arteriopathies].
    Vitoux JF; Roncato M; Pernes JM; Fiessinger JN; Aiach M; Gaux JC
    Ann Med Interne (Paris); 1986; 137(2):105-7. PubMed ID: 3717814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The fibrinolytic therapy in renal disease (author's transl)].
    Kaburagi T; Yokoyama S; Tanaka K; Haniu T; Suzuki T; Mithunami K; Takayama S; Oguma S; Hatori T; Kishimoto T; Tomimoto K
    Nihon Jinzo Gakkai Shi; 1980 Jan; 22(1):59-79. PubMed ID: 6991744
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SDS polyacrylamide gel characterization of serum FDP produced in response to ancrod and streptokinase/plasminogen infusion in man.
    Lane DA; Robbins A; Rampling MW; Kakkar VV
    Br J Haematol; 1977 May; 36(1):137-48. PubMed ID: 871418
    [No Abstract]   [Full Text] [Related]  

  • 17. Urokinase therapy: dose reduction by administration in plastic material.
    Zimmermann R; Schöffel G; Harenberg J
    Thromb Haemost; 1981 Jun; 45(3):296. PubMed ID: 7025343
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasminogen and moderate doses of urokinase in the treatment of acute pulmonary embolism.
    Griguer P; Charbonnier B; Latour F; Fauchier JP; Brochier M
    Angiology; 1979 Jan; 30(1):1-12. PubMed ID: 426316
    [No Abstract]   [Full Text] [Related]  

  • 19. [Fibrinolytic therapy of peripheral arterial occlusive disease].
    Sailer S; Pilger E
    Wien Med Wochenschr; 1985 Aug; 135(15-16):393-9. PubMed ID: 2932859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Short-term intraarterial urokinase infusion in the treatment of traumatic peripheral arterial occlusion; a case report].
    Uchino A; Onomura K; Ohno M; Tokuhisa G
    Rinsho Hoshasen; 1988 Nov; 33(12):1609-11. PubMed ID: 3221481
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.